Overall abstract Our Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution) will develop a suite of systems-based methodologies to understand how genomic diversity, clonal evolution, and phenotypic change . To evaluate their potential for translation, we will integrate these dynamic models with clinical trials that will evaluate whether these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and that simultaneously measuring and modeling subclone genotypes and phenotypes will identify new, and testable, therapeutic targets. Selective pressures from therapy and the tumor microenvironment can propel subclones from every patient's tumor along an evolutionary trajectory that leads to resistance. Indeed, our data shows that both genetic and phenotypic diversity among tumor subclones evolves as cancer cells progress to a resistant state. However, it is not yet known the specific phenotypes that promote that resistant state, the interactions among them, and how they converge to common resistant phenotypes seen in late stage cancer. To address these and other questions, we will develop a new class of dynamical systems models of subclone evolution to characterize the changes and development of key cell states that arise during acquired chemo-resistance and metastasis using our unique patient cohorts. These mechanistic models will identify points of therapeutic vulnerability that we will test in clinical trials aimed at blocking evolution to a resistant state by targeting critical resistant phenotypes. Our Center is comprised of an Administrative, Education/Outreach, Translational, and Computational Cores, in addition to two complementary projects. The synergies are derived from: 1) the convergent parameterization of the evolutionary models drawn from deep longitudinal patient progression studies (Project 1) and broad multisite metastatic tumor analyses (Project 2), resulting in a robust model to identify resistant states for clinical targeting; and 2) an integrated computational and experimental framework and resources for dissecting tumor heterogeneity and evolution that will contribute to an improved capacity for personalized cancer therapy. Our multidisciplinary team of systems biologists, bioinformaticians, tumor biologists, pharmacologists, mathematical biologists, and clinicians will tackle these scientific challenges. We will create programs to educate the next generation of scientists in systems biology and inform the community about the latest scientific advances and their impact on treatment strategies. And we will provide state of the art tools for the analysis of patient samples and tumor genomic complexity. These studies move beyond prior research by integrating cell population dynamics and cellular phenotypes with cellular genotypes, and will deliver approaches and a knowledge base to block or reverse the transition to a resistant state for advanced stage cancer patients. interact in the progression toward chemoresistant breast and ovarian cancer

Public Health Relevance

Breast and ovarian cancers are comprised of heterogeneous populations of tumors cells characterized by mutations that distinguish each cell subpopulation from one another. During treatment, tumor ?subclones?, defined as a set of unique cells within a tumor, follow unique evolutionary and resistance trajectories. Using computational tools to organize this complex variation, we will develop a new class of systems models that define subclone evolution and acquisition of oncogenic phenotypes during treatment in order to identify key chemo-resistant cell states within our patient cohorts. These mechanistic models will identify points of vulnerability for drug targeting. Our clinical trials will be aimed at blocking transition of tumors to a resistant state by blocking critical resistant phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA209978-01A1
Application #
9350520
Study Section
Special Emphasis Panel (ZCA1-RTRB-R (J2))
Program Officer
Hughes, Shannon K
Project Start
2017-05-15
Project End
2022-04-30
Budget Start
2017-05-15
Budget End
2018-04-30
Support Year
1
Fiscal Year
2017
Total Cost
$1,911,646
Indirect Cost
$556,679
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Gong, Jun; Salgia, Ravi (2018) Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract 14:359-366
Adler, Frederick R; Stockmann, Chris; Ampofo, Krow et al. (2018) Transmission of rhinovirus in the Utah BIG-LoVE families: Consequences of age and household structure. PLoS One 13:e0199388
Granchelli, Ann M; Adler, Frederick R; Keogh, Ruth H et al. (2018) Microbial Interactions in the Cystic Fibrosis Airway. J Clin Microbiol 56:
McQuerry, Jasmine A; Chang, Jeffrey T; Bowtell, David D L et al. (2017) Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. J Mol Med (Berl) 95:1167-1178
Rahman, Mumtahena; MacNeil, Shelley M; Jenkins, David F et al. (2017) Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Med 9:40
Brady, Samuel W; McQuerry, Jasmine A; Qiao, Yi et al. (2017) Combating subclonal evolution of resistant cancer phenotypes. Nat Commun 8:1231